Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Botox for Bladder Preservation After Spinal Cord Injury
NCT06793683Phase 1Enrolling by invitation
- Sponsor
- University of Washington
- Start
- Jul 2024
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of botulinum toxin type A in spinal cord injury (SCI) (2 arms), sponsored by University of Washington. Primary endpoints: Feasibility of Enrollment goals at 12 months and Number of participants with treatment-related adverse events at 12 months. Started Jul 2024; status: enrolling by invitation.
02
Drugs
botulinum toxin type A
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT06793683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793683.